You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK)公佈百悦澤®治療對BTK抑制劑不耐受復發/難治性B細胞惡性腫瘤患者安全性和有效性最新臨牀試驗數據

格隆匯12月13日丨百濟神州(06160.HK)發佈公吿,百濟神州於2021年12月11日(美國東部時間)公佈了一項正在進行的2期試驗的補充的安全性和有效性結果,這是一項評估百悦® (澤布替尼)在既往經治的、對伊布替尼和╱或Acalabrutinib不耐受的B細胞惡性腫瘤患者中療效的試驗。這些資料已於第63屆美國血液學會(ASH)年會期間於今日舉辦的一場小型口頭報吿會上披露。

百濟神州血液學首席醫學官黃蔚娟醫學博士表示:“這些試驗結果令我們深受鼓舞,進一步證明了對於經過其他BTK抑制劑治療出現不耐受的不良事件的多種晚期B細胞惡性腫瘤患者,百悦澤®具備使其獲益的潛力。百悦澤®經百濟神州科學家進行特殊設計,可通過優化激酶選擇性從而降低脱靶效應,實現對BTK蛋白的持續抑制並解決某些耐受性問題。這項治療因不良事件導致其它BTK抑制劑治療終止的患者的最新試驗結果,進一步驗證了我們既往報吿的兩項比較百悦澤®與伊布替尼的3期頭對頭試驗結果-與伊布替尼相比,百悦澤®展現出了特定的安全性優勢。”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account